Synopsis: Panacea Biotech jumped sharply after the company completed enrollment for the Phase III trial of its dengue vaccine, DengiAll®, with over 10,000 participants.
The shares of this research-based biotechnology company are in focus after it announced a key business trial, which it developed along with ICMR. In this article, we will dive more into the details of it.
With a market capitalisation of Rs 2,534 crore, the shares of Panacea Biotec Ltd reached a day’s high of Rs 422.30 per share, up 9 percent from its previous day’s closing price of Rs 383.70 per share. Over the past five years, the stock has delivered a muted return of 75 percent, underperforming NIFTY 50’s return of 81 percent.
About the Announcement
Panacea Biotec, through a stock exchange filing, announced that it has completed the enrollment phase (process of selecting and registering people for the study) for the Phase III trial of its dengue vaccine, DengiAll®. The study is being conducted in collaboration with ICMR, which is India’s leading government medical research organisation. Altogether, 10,335 participants from across India have joined the trial.
With enrollment done, participants will receive either the vaccine or a placebo (placebo means a harmless dummy injection used for comparison). Over the next two years, researchers will monitor everyone’s health to evaluate how effective the vaccine is and the strength of the immune response it generates.
If everything goes according to plan, DengiAll® will become India’s first indigenous, single-dose dengue vaccine, and the company is targeting to launch this product by 2027.
Financial and other highlights
The revenue from operations for Panacea Biotec stands at Rs 141 crores in Q2 FY26 compared to Q2 FY25 revenue of Rs 147 crores, down by about 4 per cent YoY. Additionally, on a QoQ basis, it reported a decline of 16 percent from Rs 167 crore.
Coming down to its profitability, the company’s net loss stood at Rs 14 crore in Q2 FY26, which is a sharp turnaround from a profit of Rs 5 crore in Q2 FY25. Also, on a QoQ basis, it turned around from a profit of Rs 4 crore.
Panacea Biotec, an Indian biotech company which has been operating since 1984. They began on a small scale, but by 1995, they became a public company. Their manufacturing facilities in Punjab and Himachal Pradesh adhere to international standards, and their medicines and vaccines reach about 30 countries, including regions in Asia, Africa, Latin America, the Middle East, and the CIS.
In the field of vaccines, particularly polio, Panacea Biotec holds a significant position. They supply the United Nations, helping safeguard children in over 50 countries. Throughout the years, they have introduced key vaccines, such as combination shots for children, and also produce medicines for pain, diabetes, cardiovascular diseases, cancer, and problems related to the kidneys or digestive system. They are driven by research and innovation.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock jumps 9% after successfully completing Phase III trial of its dengue vaccine appeared first on Trade Brains.